TD5A Stock Chart & Stats
€18.40
€0.10(0.68%)
At close: 4:00 PM EDT
€18.40
€0.10(0.68%)
Day’s Range― - ―
52-Week Range€10.90 - €23.09
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€999.66M
Enterprise Value€1.32B
Total Cash (Recent Filing)€456.00M
Total Debt (Recent Filing)€739.25M
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Nov 05, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding69,578,705
10 Day Avg. Volume0
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)9.53
Price to Sales (P/S)1.46
P/FCF Ratio-49.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€23.28Price Target Upside26.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-0.6
Revenue Forecast (FY)€954.18M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables EcosystemTandem combines one-time pump placements with recurring consumable purchases required for daily insulin delivery. This creates an installed-base revenue stream and increases the economic value of retaining users, while CGM interoperability and automated delivery features can support adoption.
Improving Margins And Operating TrendThe sharp gross-margin improvement and fourth consecutive quarter of positive adjusted EBITDA indicate meaningful operating progress. Reaffirmed full-year targets provide a framework for continued improvement, although the durability of profitability still depends on converting revenue growth into consistent cash earnings.
Product And Technology PipelineTandem is broadening its product and technology platform across tubeless delivery, automated insulin delivery algorithms, and major CGM integrations. These milestones can expand addressable demand and improve product relevance, supporting longer-term adoption if regulatory and launch execution succeed.
Bears Say
Elevated Financial LeverageThe thin equity cushion relative to debt materially reduces financial flexibility while Tandem is still loss-making. High leverage can constrain investment, increase sensitivity to operating setbacks, and make it harder to absorb weaker demand or fund strategic initiatives internally.
Negative Free Cash Flow And LossesTandem has improved from the prior year but is not yet consistently self-funding. Negative free cash flow alongside continuing net losses means growth and investment still consume cash, limiting resilience and making durable profitability dependent on further margin and operating improvements.
Growing Tubeless CompetitionNew patch and tubeless entrants could intensify competition in an important growth segment before Tandem’s Mobi launch is fully scaled. The company’s ability to defend adoption and economics will depend on regulatory clearance, launch timing, and demonstrating sufficient product differentiation.
TD5A FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was €10.90 and its highest was €23.09 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is €999.66M.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Nov 05, 2026 which is in 23 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on Aug 06, 2026. The company reported -€0.275 earnings per share for the quarter, beating the consensus estimate of -€0.287 by €0.013.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -0.22.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 69,578,705 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -€0.275 in its last earnings report, beating expectations of -€0.287. Following the earnings report the stock price went down -6.509%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in DE:TD5A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tandem Diabetes Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€23.28 (26.51% Upside)
€23.28 (26.51% Upside)
Blogger Sentiment
Neutral
DE:TD5A Sentiment 50%
Sector Average 66%
Sector Average 66%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.50%
12-Months-Change
Fundamentals
Return on Equity
-45.97%
Trailing 12-Months
Asset Growth
31.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
TD5A Company Deck
TD5A Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful operational and financial progress: record quarterly sales and shipments, strong international growth, notable gross margin expansion, improving profitability, and clear product and pipeline milestones (Mobi tubeless filing, AdaNet IDE). Near-term challenges include infusion set supplier constraints, a temporary revenue headwind and margin variability from the pharmacy PayGo transition, distributor destocking, and the need to accelerate U.S. new-starts in H2 to meet guidance. On balance, the positives — sizable revenue and margin improvements, product launches, and early PayGo traction — outweigh the near-term operational headwinds, with the company reiterating full-year guidance.View all DE:TD5A earnings summariesTD5A Revenue Breakdown
74.21% U.S.
25.79% International

TD5A Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€23.28
▲(26.51% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month











